Raaj Medisafe

how big is Raaj Medisafe?

As of Jun 06, Raaj Medisafe India Ltd has a market capitalization of 108.00 Cr, categorizing it as a Micro Cap company, with total assets of 41.51 Cr and shareholder's funds of 10.84 Cr as of Mar'24.

Market Cap: As of Jun 06, Raaj Medisafe India Ltd has a market capitalization of 108.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest two quarters, which includes data from Mar'16 and Mar'15, is 1.05 Cr. The sum of Net Profit for the same periods is 0.00 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 10.84 Cr, while the Total Assets amount to 41.51 Cr.

What does Raaj Medisafe do?

Raaj Medisafe India Ltd manufactures medical disposable devices and operates in the micro-cap packaging industry. As of March 2025, it reported net sales of ₹24 Cr and a net profit of ₹3 Cr, with a market cap of ₹108 Cr.

Overview:<BR>Raaj Medisafe India Ltd is engaged in the manufacturing of medical disposable devices and operates within the micro-cap segment of the packaging industry.<BR><BR>History:<BR>The company was incorporated in September 1985 under the name Manoj Surgical Industries Limited, which was later changed to Raaj Medisafe India Limited in July 2008. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 24 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 108 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 18.00<BR>- Industry P/E: 22<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.24<BR>- Return on Equity: 27.28%<BR>- Price to Book: 4.82<BR><BR>Contact Details:<BR>Address: 106 Sector III, Industrial Area Pithampur Dhar Madhya Pradesh : 454774<BR>Tel: 91-7292-403192<BR>Email: info@medisafeindia.com<BR>Website: http://www.raajmedisafeindia.com

Has Raaj Medisafe declared dividend?

No Dividend History Available

Who are the peers of the Raaj Medisafe?

Raaj Medisafe's peers include EPL Ltd, AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Shetron, AMD Industries, Guj. Containers, Orient Press, and Guj. Craft Inds. Raaj Medisafe shows excellent growth and average management risk, with a 1-year return of 22.24%, lower than Polyplex Corpn's 66.57% but higher than AMD Industries' -19.81%.

Peers: The peers of Raaj Medisafe are EPL Ltd, AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Shetron, AMD Industries, Guj. Containers, Orient Press, and Guj. Craft Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at EPL Ltd and Guj. Containers, while Average management risk is found at AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Raaj Medisafe, Shetron, and Guj. Craft Inds, and the rest. Below Average management risk is noted at AMD Industries and Orient Press. Growth is Excellent at Raaj Medisafe, Average at AGI Greenpac, TCPL Packaging, and the rest, and Below Average at EPL Ltd, Uflex, Polyplex Corpn, Shetron, AMD Industries, Guj. Containers, and Orient Press. Capital Structure is Excellent at Polyplex Corpn, Good at EPL Ltd and Guj. Containers, Average at AGI Greenpac, TCPL Packaging, and the rest, and Below Average at Uflex, Raaj Medisafe, Shetron, AMD Industries, and Orient Press.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Polyplex Corpn at 66.57%, while the lowest is AMD Industries at -19.81%. Raaj Medisafe's 1-year return of 22.24% is higher than AMD Industries but lower than Polyplex Corpn. Additionally, the six-month return is negative for Shetron, AMD Industries, and Orient Press.

Is Raaj Medisafe overvalued or undervalued?

As of May 27, 2025, Raaj Medisafe's valuation has improved to very attractive, with strong growth potential indicated by a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, making it undervalued compared to peers like Poly Medicure and Blue Jet Health, despite recent underperformance against the Sensex.

As of 27 May 2025, the valuation grade for Raaj Medisafe has moved from attractive to very attractive, indicating a positive shift in its investment appeal. The company is currently undervalued, with a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, suggesting strong growth potential relative to its price. <BR><BR>In comparison to peers, Raaj Medisafe's valuation metrics stand out, particularly when contrasted with Poly Medicure, which has a PE ratio of 66.7, and Blue Jet Health at 51.29, both categorized as very expensive. The company's return on equity (ROE) is notably high at 27.28%, further reinforcing its attractive valuation. Despite recent underperformance against the Sensex, with a year-to-date return of -8.43% compared to the Sensex's 5.59%, the long-term performance over three and five years shows significant outperformance, suggesting that the current price presents a compelling buying opportunity.

What is the technical trend for Raaj Medisafe?

As of June 3, 2025, Raaj Medisafe's technical trend is mildly bearish, influenced by daily moving averages and a monthly MACD, despite some mixed signals from the weekly MACD and Bollinger Bands.

As of 3 June 2025, the technical trend for Raaj Medisafe has changed from sideways to mildly bearish. The weekly MACD is bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, reinforcing the current trend. The Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, which contrasts with the overall bearish sentiment. The KST is bullish weekly but mildly bearish monthly, while Dow Theory indicates a mildly bearish trend on the weekly chart. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

Who are in the management team of Raaj Medisafe?

As of March 2022, the management team of Raaj Medisafe includes Arpit Bangur (Chairman), Navin Jhawar (Managing Director), and four Independent Directors: Rajesh Kumar Gupta, Vijendra Kumar Sood, and Krishna Jajoo, along with Sachin Sarda (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2022, the management team of Raaj Medisafe includes the following individuals:<BR><BR>1. Arpit Bangur - Chairman (Non-Executive)<BR>2. Rajesh Kumar Gupta - Independent Director<BR>3. Vijendra Kumar Sood - Independent Director<BR>4. Krishna Jajoo - Independent Director<BR>5. Sachin Sarda - Company Secretary & Compliance Officer<BR>6. Navin Jhawar - Managing Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the top shareholders of the Raaj Medisafe?

The top shareholders of Raaj Medisafe include Sushen Remedies Private Limited with 19.14%, individual investors with 23.05%, and Ramesh Chand Maheshvari as the highest public shareholder at 2.42%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

The top shareholders of Raaj Medisafe include the promoters, with Sushen Remedies Private Limited holding the largest stake at 19.14%. Additionally, individual investors collectively own 23.05% of the company. The highest public shareholder is Ramesh Chand Maheshvari, who holds 2.42%. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

Are Raaj Medisafe latest results good or bad?

Raaj Medisafe's latest results are positive, with a Profit After Tax of Rs 4.94 crore for the quarter ending June 2025, marking a 195.81% year-on-year growth, and net sales of Rs 15.83 crore, up 45.10% year-on-year. Overall, the company shows strong financial health and a favorable outlook.

Raaj Medisafe's latest results are quite positive. For the quarter ending June 2025, the company reported a Profit After Tax (PAT) of Rs 4.94 crore, which represents an impressive year-on-year growth of 195.81%. This significant increase indicates strong operational performance and effective management.<BR><BR>Additionally, net sales for the quarter reached Rs 15.83 crore, showing a substantial year-on-year increase of 45.10%. This growth reflects the company's ability to capture market demand effectively. Notably, the PAT for the latest six months has already exceeded the total PAT of Rs 3.35 crore from the previous twelve-month period, highlighting Raaj Medisafe's robust financial health.<BR><BR>Overall, these results underscore a strong performance and a solid position within the packaging industry, suggesting that the company's outlook is favorable.

How has been the historical performance of Raaj Medisafe?

Raaj Medisafe has shown significant growth from March 2019 to March 2025, with net sales increasing from 4.80 Cr to 62.42 Cr and a turnaround from losses to profits in operating profit, profit before tax, and profit after tax. Total assets rose from 13.59 Cr to 68.06 Cr, indicating strong financial recovery and growth.

Answer:<BR>The historical performance of Raaj Medisafe shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Raaj Medisafe's net sales have increased from 4.80 Cr in March 2019 to 62.42 Cr in March 2025, reflecting a robust growth trajectory. Total operating income followed a similar trend, rising from 4.80 Cr in March 2019 to 62.42 Cr in March 2025. The company's operating profit (PBDIT) has also improved, moving from a loss of 0.78 Cr in March 2019 to a profit of 8.83 Cr in March 2025. Profit before tax has shown a positive trend, increasing from a loss of 1.59 Cr in March 2019 to a profit of 5.25 Cr in March 2025, while profit after tax reached 6.13 Cr in March 2025, up from a loss of 1.36 Cr in March 2020. The company's total assets have expanded significantly from 13.59 Cr in March 2020 to 68.06 Cr in March 2025, with total liabilities also increasing from 13.59 Cr to 34.51 Cr during the same period. Cash flow from operating activities remained stable, while cash flow from investing activities showed a negative trend, indicating ongoing investments in growth. Overall, Raaj Medisafe has demonstrated a strong recovery and growth in its financial performance over the years.

Should I buy, sell or hold Raaj Medisafe India Ltd?

When is the next results date for Raaj Medisafe India Ltd?

The next results date for Raaj Medisafe India Ltd is 11 February 2026.

The next results date for Raaj Medisafe India Ltd is scheduled for 11 February 2026.

Which are the latest news on Raaj Medisafe?

Why is Raaj Medisafe India Ltd falling/rising?

As of 08-Feb, Raaj Medisafe India Ltd's stock price is rising to Rs 92.99, driven by strong long-term growth, consistent quarterly profits, and positive investor sentiment. The stock is trading above key moving averages and shows an attractive valuation compared to peers.

As of 08-Feb, Raaj Medisafe India Ltd's stock price is rising, currently at Rs 92.99, reflecting a change of 2.74 (3.04%) upward. This increase can be attributed to several positive factors. The company has demonstrated strong long-term growth, with net sales increasing at an annual rate of 64.38% and operating profit growing at 60.53%. Additionally, the company has reported positive results for the last three consecutive quarters, with a significant increase in profit after tax (PAT) of 152.65% and net sales reaching Rs 58.63 crore.<BR><BR>Moreover, the stock has shown consistent performance over the past year, generating a return of 32.18%, while profits have risen by 115.1%. The stock is also trading at a discount compared to its peers' average historical valuations, which suggests an attractive investment opportunity. Furthermore, the stock is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend.<BR><BR>Despite some erratic trading patterns, including a gap down opening of -4.71% today and a day low of Rs 85.9, the stock has managed to touch an intraday high of Rs 92.99. The increase in investor participation, with a delivery volume rise of 48.65% against the 5-day average, also supports the stock's upward movement. Overall, these factors contribute to the stock's rising price, reflecting positive investor sentiment and strong company fundamentals.